Stock Analiz

Shattuck Labs, Inc. STTK

Biotechnology: Pharmaceutical Preparations · IPO 2020 · data as of November 13, 2026

$4.65Market cap $474M
Open the interactive analysis →

Shattuck Labs, Inc. (STTK) is a healthcare company listed in the US with a market value of about $474M. In fiscal year 2025 it had revenue of $1M and net income of -$49M, a net margin of -4880.9%.

Its overall Stock Analiz score is 0.6 out of 5 (weak). The strongest part is financial health (2/5); the weakest is value (0/5).

Key numbers: 5-year revenue growth of -37% a year, a 5-year average ROIC of -46%.

About Shattuck Labs

Shattuck Labs is listed in the US and classified in biotechnology: pharmaceutical preparations, IPO year 2020. Revenue went from $10M in 2019 to $1M in 2025, a decline of about 31.7% a year. It was profitable in 0 of the last 7 years in our data. Its share count rose by 64% over three years (dilution for shareholders). It spends 3527% of revenue on research and development.

Score: 0.6 / 5

Value0/5
Future growth1/5
Track record0/5
Financial health2/5
Shareholder returns0/5

Checks passed

  • 3-year revenue growth above 10% a year
  • More cash than debt, or low debt to equity
  • Liabilities below 60% of assets

Checks not passed

  • P/E below 25
  • P/E below the industry median
  • P/FCF below 20
  • Price below intrinsic value (DCF, moderate assumptions)
  • PEG below 1.5
  • Revenue growth above 10% last year
  • Profit margin improving
  • 3-year free cash flow growth above 10% a year

Valuation

P/E (TTM)—
Forward P/E—
P/FCF—
P/S—
P/B2.4
EV/EBITDA—
PEG—
Dividend yield0.00%
FCF yield-10.5%
Shareholder yield0.0%
Intrinsic value vs. price—

Growth and quality

Revenue growth (1 yr)-82.5%
Revenue growth (5 yrs, per year)-36.8%
EPS growth (5 yrs, per year)—
FCF growth (3 yrs, per year)—
Net margin (5-yr avg.)-5450.6%
ROIC (5-yr avg.)-46.3%
Profitable years (of last 10)0
Years paying a dividend—

Financials, last 7 years

Fiscal year2025202420232022202120202019
Revenue$1M$6M$2M$652000$30M$10M$10M
Net income-$49M-$75M-$87M-$102M-$45M-$37M-$24M
Free cash flow-$40M-$61M-$82M-$106M-$65M-$34M-$21M
EPS (diluted)$-0.70$-1.49$-2.05$-2.41$-1.07$-2.36$-3.17
Net margin-4880.9%-1318.1%-5268.4%-15635.7%-149.8%-368.5%-242.6%
ROIC-48.0%-76.6%-48.8%-45.1%-13.2%-9.4%—

From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.

What analysts expect

The average 12-month price target from 10 analysts is $15.40, 231% above the current price; targets range from $10.00 to $19.00; the consensus rating is “Strong buy”; expected EPS is $-0.55 for the fiscal year ending December 31, 2026.

Frequently asked questions

Does Shattuck Labs pay a dividend?

Not currently.

Is Shattuck Labs a good stock to buy?

We do not give buy or sell advice. Shattuck Labs scores 0.6 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.

Similar companies

Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.